PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
2.740
+0.020 (0.74%)
Mar 31, 2025, 9:30 AM EDT - Market open
PolyPid Employees
As of December 31, 2024, PolyPid had 60 total employees, including 57 full-time and 3 part-time employees. The number of employees decreased by 2 or -3.23% compared to the previous year.
Employees
60
Change (1Y)
-2
Growth (1Y)
-3.23%
Revenue / Employee
n/a
Profits / Employee
-$483,700
Market Cap
27.92M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PYPD News
- 20 days ago - PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections - GlobeNewsWire
- 4 weeks ago - PolyPid to Participate in the 37th Annual ROTH Conference - GlobeNewsWire
- 6 weeks ago - PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 2 months ago - PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025 - GlobeNewsWire
- 3 months ago - Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday - Benzinga
- 3 months ago - PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million - GlobeNewsWire